Back to team
Vincent Ossipow
LinkedIn
Partner
Vincent joined Omega Funds in 2014. Vincent has held investor positions with NeoMed Management and Sectoral Asset Management. Previously, he was a biotech equities research analyst at Pictet Bank and fund co-manager of the Pictet Biotech Fund. Vincent currently serves on the Board of Directors of Callio Therapeutics and is a board observer at Anaconda BioMed. He previously served on the Board of Directors for Immunic Therapeutics (Nasdaq: IMUX), BioInvent AB (OMXS: BINV), and FoRx Therapeutics.
Vincent completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business and holds an MS in Computational Sciences, an MS in Molecular Biology, and a Ph.D. in Molecular Biology, all from the University of Geneva.